Moderna's mRNA flu shot earns FDA approval after rollercoaster review

Per Ars Technica, the FDA on Thursday granted approval for Moderna's mRNA flu vaccine, mFLUSIVA—marking the first such vaccine to win authorization. The shot is approved for adults fifty and older and demonstrated superior efficacy against the flu compared to traditional vaccines, based on trials with nearly forty-four thousand participants. FDA advisors had unanimously backed the approval in June, though the vaccine's path remained uncertain given Health Secretary Robert F. Kennedy Jr.'s known skepticism of vaccines.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton